Yêu cầu chức năng của một alen hoang dã cho IDH1 đột biến để ức chế sự tăng trưởng độc lập với giá đỡ thông qua cân bằng redox

Bardella C, Al-Dalahmah O, Krell D, Brazauskas P, Al-Qahtani K, Tomkova M et al (2016) Expression of Idh1R132H in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis. Cancer Cell 30:578–594. https://doi.org/10.1016/j.ccell.2016.08.017 Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S et al (2014) Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer 120:2440–2447. https://doi.org/10.1002/cncr.28732 Borodovsky A, Salmasi V, Turcan S, Fabius AWM, Baia GS, Eberhart CG et al (2013) 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 4:1737–1747 Bralten LBC, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M et al (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 69:455–463. https://doi.org/10.1002/ana.22390 Cairns RA, Mak TW (2013) Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 3:730–741. https://doi.org/10.1158/2159-8290.CD-13-0083 Cancer Genome Atlas Research Network (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/NEJMoa1402121 Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028 Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A et al (2014) Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Natl Acad Sci USA 111:14217–14222. https://doi.org/10.1073/pnas.1409653111 Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA et al (2014) Lactate dehydrogenase A silencing in IDH mutant gliomas. Neurooncology 16:686–695. https://doi.org/10.1093/neuonc/not243 Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J et al (2015) Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. PLoS ONE 10:e0125125. https://doi.org/10.1371/journal.pone.0125125 Chowdhury R, Yeoh KK, Tian Y-M, Hillringhaus L, Bagg EA, Rose NR et al (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463–469. https://doi.org/10.1038/embor.2011.43 Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744. https://doi.org/10.1038/nature08617 Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD (2014) Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510:298–302. https://doi.org/10.1038/nature13236 Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:13–27. https://doi.org/10.1016/j.ccr.2009.11.020 Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y et al (2015) 2-Hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab 22:508–515. https://doi.org/10.1016/j.cmet.2015.06.009 Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM et al (1999) Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59:4228–4232 Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE et al (2015) Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist 20:1019–1027. https://doi.org/10.1634/theoncologist.2015-0210 Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X et al (2014) IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res 74:3317–3331. https://doi.org/10.1158/0008-5472.CAN-14-0772-T Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344. https://doi.org/10.1084/jem.20092506 Holmen SL, Williams BO (2005) Essential role for Ras signaling in glioblastoma maintenance. Cancer Res 65:8250–8255. https://doi.org/10.1158/0008-5472.CAN-05-1173 Huang LE, Arany Z, Livingston DM, Bunn HF (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271:32253–32259 Huang LE, Cohen AL, Colman H, Jensen RL, Fults DW, Couldwell WT (2017) IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget 8:191–202. https://doi.org/10.18632/oncotarget.13329 Itsumi M, Inoue S, Elia AJ, Murakami K, Sasaki M, Lind EF et al (2015) Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)/NADPH ratio. Cell Death Differ 22:1837–1845. https://doi.org/10.1038/cdd.2015.38 Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM et al (2015) IDH1 mutation induces reprogramming of pyruvate metabolism. Cancer Res 75:2999–3009. https://doi.org/10.1158/0008-5472.CAN-15-0840 Jeon S-M, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485:661–665. https://doi.org/10.1038/nature11066 Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA et al (2016) Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532:255–258. https://doi.org/10.1038/nature17393 Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA et al (2013) Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 73:496–501. https://doi.org/10.1158/0008-5472.CAN-12-2852 Kim JH, Lee S-R, Li L-H, Park H-J, Park J-H, Lee KY et al (2011) High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS ONE 6:e18556. https://doi.org/10.1371/journal.pone.0018556 Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S et al (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484–488. https://doi.org/10.1038/nature10898 Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482–4490. https://doi.org/10.1200/JCO.2010.33.8715 Loftus SK, Larson DM, Watkins-Chow D, Church DM, Pavan WJ (2001) Generation of RCAS vectors useful for functional genomic analyses. DNA Res 8:221–226 Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478. https://doi.org/10.1038/nature10860 Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ et al (2012) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neurooncology 14:184–191. https://doi.org/10.1093/neuonc/nor207 Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058–1066. https://doi.org/10.1056/NEJMoa0903840 Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J et al (2015) Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. Cancer Res 75:4790–4802. https://doi.org/10.1158/0008-5472.CAN-14-3603 Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812. https://doi.org/10.1126/science.1164382 Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636–3643. https://doi.org/10.1200/JCO.2010.28.3762 Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27–47. https://doi.org/10.1016/j.cmet.2015.12.006 Pusch S, Schweizer L, Beck A-C, Lehmler J-M, Weissert S, Balss J et al (2014) D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathol Commun 2:19. https://doi.org/10.1186/2051-5960-2-19 Robinson JP, Vanbrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL (2010) Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 29:335–344. https://doi.org/10.1038/onc.2009.333 Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–630. https://doi.org/10.1126/science.1236062 Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS et al (2014) Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513:110–114. https://doi.org/10.1038/nature13441 Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio IIC et al (2012) D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26:2038–2049. https://doi.org/10.1101/gad.198200.112 Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A et al (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488:656–659. https://doi.org/10.1038/nature11323 Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY et al (2009) Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461:109–113. https://doi.org/10.1038/nature08268 Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019 Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M et al (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:101–105. https://doi.org/10.1038/nature12040 Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468. https://doi.org/10.1038/ng.3273 Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N et al (2015) Extreme Vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell 28:773–784. https://doi.org/10.1016/j.ccell.2015.11.006 Turcan S, Fabius AWM, Borodovsky A, Pedraza A, Brennan C, Huse J et al (2013) Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 4:1729–1736 Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483. https://doi.org/10.1038/nature10866 Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K et al (2014) Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 20:2898–2909. https://doi.org/10.1158/1078-0432.CCR-13-3052 Wang F, Travins J, Delabarre B, Penard-Lacronique V, Schalm S, Hansen E et al (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622–626. https://doi.org/10.1126/science.1234769 Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK et al (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288:3804–3815. https://doi.org/10.1074/jbc.M112.435495 Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234. https://doi.org/10.1016/j.ccr.2010.01.020 Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153. https://doi.org/10.2353/ajpath.2009.080958 von Werder A, Seidler B, Schmid RM, Schneider G, Saur D (2012) Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system. Nat Protoc 7:1167–1183. https://doi.org/10.1038/nprot.2012.060 Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30. https://doi.org/10.1016/j.ccr.2010.12.014 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710 Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C et al (2011) DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neurooncology 13:280–289. https://doi.org/10.1093/neuonc/noq190